We are live on
!
Find out more
DCM
DAFNA Capital Management Portfolio holdings
AUM
$524M
1-Year Est. Return
164.42%
This Fund
S&P 500
This Quarter
Est. Return
+9.56%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$362M
AUM Growth
+$9.59M
(+2.7%)
Cap. Flow
-$13M
Cap. Flow
% of AUM
-3.59%
Top 10 Holdings %
Top 10 Hldgs %
55.78%
Holding
86
New
3
Increased
22
Reduced
21
Closed
10
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BPMC
Blueprint Medicines
BPMC
|
+$1.71M |
| 2 |
BCAX
Bicara Therapeutics
BCAX
|
+$1.25M |
| 3 |
Compass Therapeutics
CMPX
|
+$1.09M |
| 4 |
DAWN
Day One Biopharmaceuticals
DAWN
|
+$1.02M |
| 5 |
Inogen
INGN
|
+$992K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioCryst Pharmaceuticals
BCRX
|
+$3.17M |
| 2 |
MRUS
Merus
MRUS
|
+$2.96M |
| 3 |
TSVT
2seventy bio
TSVT
|
+$2.12M |
| 4 |
KALV
KalVista Pharmaceuticals
KALV
|
+$2.09M |
| 5 |
RGLS
Regulus Therapeutics
RGLS
|
+$1.48M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 85.53% |
| 2 | Miscellaneous | 14.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
State Street SPDR S&P Biotech ETF
XBI
$11.3B
| $34.5M | 9.51% |
415,505
+11,000
| +3% | +$878K |
|
2
Stereotaxis
STXS
$145M
| $29M | 8.01% |
13,680,554
| – | – |
|
3
Revolution Medicines
RVMD
$44.6B
| $24.9M | 6.88% |
677,176
+21,000
| +3% | +$807K |
|
|
BPMC
4
DELISTED
Blueprint Medicines
BPMC
| $21.6M | 5.97% |
168,763
+16,500
| +11% | +$1.71M |
|
|
MRUS
5
DELISTED
Merus
MRUS
| $21M | 5.79% |
398,804
-63,000
| -14% | -$2.96M |
|
6
AtriCure
ATRC
$2.47B
| $19.4M | 5.36% |
592,273
| – | – |
|
7
Cytokinetics
CYTK
$10B
| $13.2M | 3.63% |
398,100
| – | – |
|
8
IDEAYA Biosciences
IDYA
$3.87B
| $13M | 3.59% |
619,090
+29,760
| +5% | +$571K |
|
9
iShares Biotechnology ETF
IBB
$10.5B
| $13M | 3.58% |
102,500
| – | – |
|
10
Ascendis Pharma A/S
ASND
$16.3B
| $12.5M | 3.46% |
72,677
-7,721
| -10% | -$1.26M |
|
11
Xenon Pharmaceuticals
XENE
$5.81B
| $9.01M | 2.49% |
287,939
+14,200
| +5% | +$463K |
|
12
Neurocrine Biosciences
NBIX
$15.7B
| $8.88M | 2.45% |
70,615
-1,000
| -1% | -$115K |
|
13
Axogen
AXGN
$2.77B
| $8.05M | 2.22% |
741,782
+61,000
| +9% | +$799K |
|
|
KALV
14
DELISTED
KalVista Pharmaceuticals
KALV
| $6.58M | 1.82% |
581,757
-170,602
| -23% | -$2.09M |
|
15
DexCom
DXCM
$34.3B
| $5.72M | 1.58% |
65,552
| – | – |
|
|
DAWN
16
DELISTED
Day One Biopharmaceuticals
DAWN
| $5.71M | 1.58% |
879,163
+147,800
| +20% | +$1.02M |
|
17
Stoke Therapeutics
STOK
$2.04B
| $5.7M | 1.57% |
501,972
+57,974
| +13% | +$550K |
|
18
Tandem Diabetes Care
TNDM
$1.49B
| $5.48M | 1.51% |
294,208
| – | – |
|
19
Arcus Biosciences
RCUS
$3.72B
| $5.11M | 1.41% |
627,626
+2,500
| +0.4% | +$21.4K |
|
20
Syndax Pharmaceuticals
SNDX
$1.74B
| $5.09M | 1.41% |
543,602
-900
| -0.2% | -$9.91K |
|
21
Mineralys Therapeutics
MLYS
$2.26B
| $5.03M | 1.39% |
371,523
+62,323
| +20% | +$903K |
|
22
UroGen Pharma
URGN
$2.13B
| $4.79M | 1.32% |
349,515
-143,000
| -29% | -$1.37M |
|
|
23
Inogen
INGN
$146M
| $4.26M | 1.18% |
605,625
+147,560
| +32% | +$992K |
|
|
LKFT
24
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
| $3.64M | 1.01% |
130,175
| – | – |
|
25
Biohaven
BHVN
$2.33B
| $3.32M | 0.92% |
235,235
+15,000
| +7% | +$267K |
|
Similar funds
4WM
BB
A
HW
DAM
SDWIA
SCA
BHPW
DAFNA Capital Management's Q2 2025 Portfolio in Review
As of Q2 2025, DAFNA Capital Management held 86 positions worth $362M, up 2.7% from $353M the previous quarter. Its ten largest holdings account for 56% of the portfolio.
DAFNA Capital Management withdrew a net $13M in Q2 2025, closing 10 positions and reducing 21 holdings. Its most notable exit was 2seventy bio, an estimated $2.12M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 86% a quarter earlier, followed by Miscellaneous.
Against the trend, DAFNA Capital Management opened a new position in Compass Therapeutics worth $1.37M.
- DAFNA Capital Management's largest Q2 2025 buy was Compass Therapeutics: 526,660 shares worth $1.37M.
- DAFNA Capital Management added most to Blueprint Medicines in Q2 2025, an estimated $1.71M increase.
- DAFNA Capital Management's biggest Q2 2025 reduction was BioCryst Pharmaceuticals, cutting an estimated $3.17M.
- DAFNA Capital Management fully exited 2seventy bio in Q2 2025, selling an estimated $2.12M.
- DAFNA Capital Management's ten largest holdings make up 56% of its $362M portfolio in Q2 2025.
- DAFNA Capital Management opened 3 new positions and closed 10 in Q2 2025.
- DAFNA Capital Management's portfolio value rose 2.7% quarter-over-quarter to $362M.
Based on DAFNA Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.